Last reviewed · How we verify
PTC596
At a glance
| Generic name | PTC596 |
|---|---|
| Sponsor | PTC Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma (PHASE1)
- A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) (PHASE2, PHASE3)
- Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy (PHASE1)
- A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) (PHASE1)
- PTC596 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PTC596 CI brief — competitive landscape report
- PTC596 updates RSS · CI watch RSS
- PTC Therapeutics portfolio CI